Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from AFT Pharmaceuticals Ltd. ( (AU:AFP) ).
AFT Pharmaceuticals has accelerated its international expansion and R&D programmes in the December quarter of FY26, acquiring the hospital division of Cape Town-based Pharma Dynamics to build its South African and broader African hospital presence, progressing the commercialisation of products acquired in Europe with launches planned across several EU markets, and preparing a series of new product rollouts in Canada, the UK and South Africa in FY27. The company also signed a significant agreement with UK firm Stablepharma to co-develop room-temperature formulations of currently refrigerated injectable medicines, targeting a global addressable market of more than US$6 billion, supported by a new banking facility from BNZ and strong operating cashflows as AFT reiterates its FY26 earnings guidance and pursues a FY27 revenue goal of $300 million.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals is the largest New Zealand-based pharmaceuticals company, developing and commercialising prescription and over-the-counter medicines across Australasia and an expanding network of international hubs, including South Africa, Europe, Canada and the UK. Its portfolio spans hospital products, pain relief brands such as Maxigesic/Combogesic, and growing R&D capabilities focused on innovative formulations and delivery technologies for global markets.
Average Trading Volume: 2,433
Technical Sentiment Signal: Buy
Current Market Cap: A$319.5M
Learn more about AFP stock on TipRanks’ Stock Analysis page.